<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03062059</url>
  </required_header>
  <id_info>
    <org_study_id>InstiGem</org_study_id>
    <nct_id>NCT03062059</nct_id>
  </id_info>
  <brief_title>The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence</brief_title>
  <official_title>The Effectiveness and Safety of Intravesical Gemcitabine Instillation During Operation to Prevent Intravesical Recurrence After Radical Nephroureterectomy in Upper Urinary Tract Urothelial Carcinoma: Prospective, Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chong Kun Dang Pharmaceutical Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effectiveness and safety of intravesical gemcitabine
      instillation during operation to prevent intravesical recurrence after radical
      nephroureterectomy in upper urinary tract urothelial carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: Intervention Model: Single Group Assignment

      Masking: Open Label

      Primary Outcome Measures:

      Two year recurrence-free survival in intravesical 2000mg/52.6ml gemcitabine instillation
      group and control group.

      Secondary Outcome Measures:

      Time to recurrence in intravesical 2000mg/52.6ml gemcitabine instillation group and control
      group.

      Overall survival in intravesical 2000mg/52.6ml gemcitabine instillation group and control
      group.

      Safety of intravesical 2000mg/52.6ml gemcitabine instillation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Two year recurrence-free survival in intravesical 2000mg/52.6ml gemcitabine instillation group and control group. The recurrence will be assessed by CT scan and cystoscopic exam.</measure>
    <time_frame>Two years</time_frame>
    <description>Analysis of recurrence status at 2 years from intravesical instillation of 2000mg/52.6ml gemcitabine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence in intravesical 2000mg/52.6ml gemcitabine instillation group and control group. The recurrence will be assessed by CT scan and cystoscopic exam.</measure>
    <time_frame>six years</time_frame>
    <description>Analysis of time from starting intravesical instillation of 2000mg/52.6ml gemcitabine to recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival in intravesical 2000mg/52.6ml gemcitabine instillation group and control group.</measure>
    <time_frame>six years</time_frame>
    <description>Analysis of survival status due to any cause at six years from intravesical instillation of 2000mg/52.6ml gemcitabine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CT cystography finding at one week after surgery.</measure>
    <time_frame>one week</time_frame>
    <description>Evaluation of leakage at CT cystography at one week from intravesical instillation of 2000mg/52.6ml gemcitabine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Prostate Symptom Score questionnaire at one week after surgery.</measure>
    <time_frame>one week</time_frame>
    <description>Evaluation of survey with International Prostate Symptom Score questionnaire a one week after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravesical 2000mg/52.6ml gemcitabine instillation during radical nephroureterectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravesical 2000mg/52.6ml gemcitabine instillation</intervention_name>
    <description>Intravesical 2000mg/52.6ml gemcitabine instillation during operation to prevent intravesical recurrence after radical nephroureterectomy in upper urinary tract urothelial carcinoma</description>
    <arm_group_label>Intervention arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subjects who will undergo nephroureterectomy due to ureter or renal pelvis
             urothelial carcinoma

          -  Male or female aged 18 or over 18 years and not more than 85 years who were diagnosed
             as upper urinary tract urothelial carcinoma

          -  Normal bone marrow function: Hemoglobin &gt;10 g/dL, ANC &gt;1,500/mm3, platelet
             count&gt;100,000/mm3

          -  Normal bladder volume and function

          -  Normal liver function:

          -  Bilirubin ≤ 1.5 times of upper normal limit

          -  AST/ALT ≤ 1.8 times of upper normal limit

          -  Alkaline phosphatase ≤ 1.8 times of upper normal limit

          -  Subjects who voluntarily decided to participate and signed the written informed
             consent

        Exclusion Criteria:

          -  Concomitant bladder cancer

          -  Subjects who underwent any treatment due to bladder cancer within 3 years

          -  Prior hypersensitivity reaction history to gemcitabine

          -  Neurogenic bladder

          -  Subjects who underwent chemotherapy due to any cancer within 6 months

          -  Subjects who underwent neoadjuvant chemotherapy due to ureter or renal pelvis
             urothelial carcinoma

          -  Hypersensitivity to gemcitabine or component of gemcitabine

          -  In case of co-administration of gemcitabine and cisplatin in severe renal failure
             patients

          -  Moderate to severe liver dysfunction or renal dysfunction (Glomerular filtration rate
             &lt; 30 mL/min)

          -  Severe bone marrow suppression

          -  Severe infection

          -  Female who are pregnant or has a possibility of pregnancy

          -  Nursing female

          -  Interstitial pneumonia or pulmonary fibrosis which is evident on chest x-ray and
             symptomatic

          -  Subjects who are undergoing radiotherapy on chest
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ho Kyung Seo, M.D.</last_name>
    <phone>82-31-920-1678</phone>
    <email>seohk@ncc.re.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yoon Seok Suh, M.D.</last_name>
    <phone>82-10-5019-9807</phone>
    <email>12754@ncc.re.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ho Kyung Seo, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Jinsoo Chung, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sung Han Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bum Sik Hong, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seok Ho Kang, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byong Chang Jeong, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ja Hyun Ku, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2017</study_first_submitted>
  <study_first_submitted_qc>February 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Ho Kyung Seo</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

